Is glucagon-like peptide 1 an incretin hormone?

Diabetologia

Volumn 42, Issue 3, 1999, Pages 373-379

  Nauck, Michael A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Gastric emptying; Glucagon; Glucagon like peptide 1; Ileal brake; Incretin hormones; Insulin; Motility

Indexed keywords

ANTISERUM; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HORMONE RECEPTOR; INSULIN;

ANIMAL EXPERIMENT; BABOON; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; INSULIN RELEASE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; L CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; REVIEW; RODENT; STOMACH EMPTYING;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIGESTION; GASTRIC EMPTYING; GASTROINTESTINAL HORMONES; GASTROINTESTINAL MOTILITY; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; INSULIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0033028297     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051165     Document Type: Review

References (67)

1. 1. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC (1983) Exon duplication and divergence in the human pre-proglucagon gene. Nature 304: 368-371
2. 2. Schmidt WE, Siegel EG, Creutzfeldt W (1985) Glucagon-like peptide 1 but not glucagon-like peptide 2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28: 704-707
3. 3. Creutzfeldt W (1979) The incretin concept today. Diabetologia 16: 75-85
4. 4. Tillil H, Shapiro ET, Miller A et al. (1988) Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol (Endocrinol Metab) 254: E349-E357
5. 5. Nauck MA, Homberger E, Siegel EG et al. (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498
6. 6. Brown JC (1982) Gastric inhibitory polypeptide. Monographs in Endocrinology, vol 24. Springer Verlag, Berlin Heidelberg New York
7. 7. Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet II: 1300-1304
8. 8. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917
9. 9. Creutzfeldt W, Nauck M (1992) Gut hormones and diabetes mellitus. Diabetes Metab Rev 8: 149-177
10. 10. Ebert R, Creutzfeldt W (1982) Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinology 111: 1601-1606
11. 11. Ebert R, Unger H, Creutzfeldt W (1983) Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 24: 449-454
12. 12. Holst JJ, Orskov C, Vagn-Nielsen O, Schwartz TW (1987) Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 211: 169-174
13. 13. Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616-619
14. 14. Holst JJ (1994) Glucagonlike peptide 1: a newly discover-edgastrointestinal hormone. Gastroenterology 107: 1848-1855
15. 15. Fehmann HC, Göke R, Göke B (1995) Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrinol Rev 16: 390-410
16. 16. Nauck MA (1997) Glucagonlike peptide 1. Curr Opin Endocrinol Diabetes 4: 256-261
17. 17. Eissele R, Göke R, Willemer S et al. (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22: 283-291
18. 18. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43: 535-539
19. 19. Ørskov C, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV, Holst JJ (1986) Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119: 1467-1475
20. 20. Herrmann-Rinke C, Vöge A, Hess M, Göke B (1995) Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol 147: 25-31
21. 21. Layer P, Holst JJ, Grandt D, Goebell H (1995) Heal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 40: 1074-1082
22. 22. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117-126
23. 23. Nauck MA, Siemsglüß J, Ørskov C, Holst JJ (1996) Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Z Gastroenterol 34: 159-166
24. 24. Schirra J, Katschinski M, Weidmann C et al. (1996) Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97: 92-103
25. 25. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W (1995) Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 30: 892-896
26. 26. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307
27. 27. Gray GM (1970) Carbohydrate digestion and absorption. Gastroenterol 58: 96-107
28. 28. Krarup T (1988) Immunoreactive gastric inhibitory polypeptide. Endocrinol Rev 9: 122-133
29. 29. Brubaker PL (1991) Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 128: 3175-3182
30. 30. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957
31. 2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44: 1126-1131
32. 32. Göke R, Conlon JM (1988) Receptors for glucagon-like peptide-1 (7-36) amide on rat insulinoma-derived cells. J Endocrinol 116: 357-362
33. 33. Thorens B (1992) Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89: 8641-8645
34. 34. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C (1993) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682
35. 35. Wei Y, Mojsov S (1995) Tissue-specific expression of the human receptor for glucagon-like peptide-I:brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358: 219-224
36. 36. Göke R, Trautmann ME, Haus E et al. (1989) Signal transmission after GLP-1(7-36) amide binding in RINm5F cells. Am J Physiol 257: G397-G401
37. 37. Holz GG, Leech CA, Habener JF (1995) Activation of a cAMP-regulated Ca(2 + )-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270: 17749-17757
38. 38. Kolligs F, Fehmann HC, Göke R, Göke B (1995) Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19
39. 39. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W (1995) Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32: 13-16
40. 40. Moens K, Heimberg H, Flamez D et al. (1996) Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45: 257-261
41. 41. Ørskov C, Holst JJ, Nielsen OV (1988) Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123: 2009-2013
42. 42. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M (1998) Exendin (9-39)amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Invest 101: 1421-1430
43. 43. Fehmann HC, Gherzi R, Göke B (1995) Regulation of islet hormone gene expression by incretin hormones. Exp Clin Endocrinol Diabetes 103 [Suppl 2]: 56-65
44. 44. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ (1993) Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673
45. 45. Nauck MA, Niedereichholz U, Ettler R et al. (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273: E981-E988
46. 46. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332
47. 47. Schjoldager BT, Mortensen PE, Christiansen J, Ørskov C, Holst JJ (1989) GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 34: 703-708
48. 48. Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ (1994) Glucagon-like Peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 29: 501-505
49. 49. Turton MD, D OS, Gunn I et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72
50. 50. Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520
51. 51. Gutniak MK, Holst JJ, Ørskov C, Åhren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-1322
52. 52. Valverde I, Villanueva Penacarrillo ML (1996) In vitro insulinomimetic effects of GLP-1 in liver, muscle and fat. Acta Physiol Scand 157: 359-360
53. 53. Toft-Nielsen M-B, Madsbad S, Holst JJ (1996) The effect of glucagon-like peptide I (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45: 552-556
54. 54. Ørskov L, Holst J, Moller J et al. (1996) GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 1227-1232
55. 55. Göke R, Fehmann HC, Linn T et al. (1993) Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268: 19650-19655
56. 56. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR (1995) Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95: 417-421
57. 57. Scrocchi LA, Brown TJ, MaClusky N et al. (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258
58. 58. D' Alessio D, Vogel R, Prigeon R et al. (1996) Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest: 133-138
59. 59. Tseng C-C, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM (1996) Postprandial stimulation of insulin release by glucose-dependent insulinotropic peptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98: 2440-2445
60. 60. Jia X, Brown JC, Ma P, Pederson RA, McIntosh CH (1995) Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. Am J Physiol 268: E645-E651
61. 61. Jones IR, Owens DR, Moody AJ, Luzio SD, Morris T, Hayes TM (1987) The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 30: 707-712
62. 62. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744
63. 63. Nauck MA, Holst JJ, Willms B, Schmiegel W (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes. Exp Clin Endocrinol Diabet 105: 187-195
64. 64. Göke B, Fuder H, Wieckhorst G et al. (1995) Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 56: 493-501
65. 65. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA (1998) Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med 15: 485-491
66. 66. Besterman HS, Bloom SR, Sarson DL et al. (1978) Guthormone profile in coeliac disease. Lancet I: 785-788
67. 67. Edwards CMB, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR (1999) Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans. Studies with the antagonist exendin 9-39. Diabetes 48: 86-93